Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYAD
CUSIPN/A
Phone321-039-4100
Debt
Debt-to-Equity Ratio0.02
Current Ratio4.58
Quick Ratio4.58
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$4 million
Price / Sales74.10
Cash FlowN/A
Price / CashN/A
Book Value$5.44 per share
Price / Book5.52
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees88
Outstanding Shares9,870,000
Market Cap$296.47
CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions
What is CELYAD SA/ADR's stock symbol?
CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD."
What price target have analysts set for CYAD?
4 brokers have issued 12-month price objectives for CELYAD SA/ADR's stock. Their predictions range from $44.00 to $74.00. On average, they anticipate CELYAD SA/ADR's share price to reach $53.00 in the next year. This suggests a possible upside of 76.5% from the stock's current price. View Analyst Ratings for CELYAD SA/ADR.
What is the consensus analysts' recommendation for CELYAD SA/ADR?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of CELYAD SA/ADR's key competitors?
Some companies that are related to CELYAD SA/ADR include Tricida (TCDA), Esperion Therapeutics (ESPR), Wave Life Sciences (WVE), Intra-Cellular Therapies (ITCI), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), Flexion Therapeutics (FLXN), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), Omeros (OMER), TG Therapeutics Inc common stock (TGTX), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX) and AC Immune (ACIU).
Who are CELYAD SA/ADR's key executives?
CELYAD SA/ADR's management team includes the folowing people:
- Mr. Michel E. Lussier MS BME, MBA, Co-Founder & Chairman (Age 62)
- Dr. Christian Homsy M.D., MBA, CEO & Exec. Director (Age 60)
- Mr. Patrick Jeanmart, Chief Financial Officer & Investor Relations (Age 46)
- Dr. Jean-Pierre Latere, Chief Operating Officer (Age 43)
- Mr. Philippe Dechamps, Chief Legal Officer (Age 48)
When did CELYAD SA/ADR IPO?
(CYAD) raised $99 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
Has CELYAD SA/ADR been receiving favorable news coverage?
Press coverage about CYAD stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CELYAD SA/ADR earned a media sentiment score of 0.01 on Accern's scale. They also gave news stories about the company an impact score of 45.92 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of CELYAD SA/ADR?
Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELYAD SA/ADR's stock price today?
One share of CYAD stock can currently be purchased for approximately $30.03.
How big of a company is CELYAD SA/ADR?
CELYAD SA/ADR has a market capitalization of $296.47 million and generates $4 million in revenue each year. The company earns $-63,740,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. CELYAD SA/ADR employs 88 workers across the globe.
How can I contact CELYAD SA/ADR?
CELYAD SA/ADR's mailing address is Rue Edouard Belin 2, Mont-Saint-Guibert C9, 1435. The company can be reached via phone at 321-039-4100.
MarketBeat Community Rating for CELYAD SA/ADR (NASDAQ CYAD)
MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
